Thu, March 6, 2025
Wed, March 5, 2025
Tue, March 4, 2025

Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ks-q4-in-review-amneal-nasdaq-amrx-vs-peers.html
  Print publication without navigation Published in Stocks and Investing on by MSN
          🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source


  Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The generic pharmaceutical industry operates on a volume-driven,

The article from MSN Money discusses the performance of generic pharmaceuticals stocks in the fourth quarter, focusing on Amneal Pharmaceuticals (NASDAQ: AMRX) and comparing it with its peers. Amneal experienced a significant stock price increase of 100% over the last year, driven by a robust Q4 performance where it reported a 13% year-over-year revenue growth to $617.8 million, surpassing expectations. This growth was attributed to strong sales in its generics and specialty segments. However, despite the positive revenue figures, Amneal's net loss widened to $13.7 million from $1.3 million the previous year, due to increased operating expenses and interest costs. The article also mentions that while Amneal outperformed some of its peers in stock price growth, companies like Teva Pharmaceutical Industries and Viatris Inc. faced different challenges, with Teva dealing with legal issues and Viatris focusing on restructuring efforts. Overall, the sector shows mixed results with Amneal standing out for its revenue growth but still grappling with profitability issues.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/savingandinvesting/generic-pharmaceuticals-stocks-q4-in-review-amneal-nasdaq-amrx-vs-peers/ar-AA1Ai0IY ]

Publication Contributing Sources